Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBT (2016 - 2025)

Historic EBT for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $1.2 million.

  • Akebia Therapeutics' EBT rose 10576.38% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.3 million, marking a year-over-year increase of 6675.51%. This contributed to the annual value of -$69.4 million for FY2024, which is 3367.36% down from last year.
  • Akebia Therapeutics' EBT amounted to $1.2 million in Q3 2025, which was up 10576.38% from $247000.0 recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' EBT peaked at $29.0 million during Q2 2022, and registered a low of -$84.3 million during Q2 2021.
  • For the 5-year period, Akebia Therapeutics' EBT averaged around -$26.0 million, with its median value being -$18.0 million (2024).
  • In the last 5 years, Akebia Therapeutics' EBT soared by 13444.48% in 2022 and then crashed by 381400.65% in 2024.
  • Over the past 5 years, Akebia Therapeutics' EBT (Quarter) stood at -$70.4 million in 2021, then skyrocketed by 90.76% to -$6.5 million in 2022, then skyrocketed by 109.44% to $614000.0 in 2023, then tumbled by 3814.01% to -$22.8 million in 2024, then soared by 105.06% to $1.2 million in 2025.
  • Its EBT was $1.2 million in Q3 2025, compared to $247000.0 in Q2 2025 and $6.1 million in Q1 2025.